March
16, 2023
VIA FACSIMILE AND EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporate Finance
Washington,
DC 20549
|
Re:
|
|
Dermata Therapeutics, Inc.
|
|
|
|
Registration Statement on Form S-1 (Registration No. 333-270195),
as amended - Concurrence in Acceleration Request
|
Ladies
and Gentlemen:
H.C.
Wainwright & Co., LLC (“Wainwright”), solely
acting as placement agent on a best efforts basis in an offering
pursuant to the registration statement on Form S-1 (333-270195)
(the “Registration
Statement”), hereby concurs in the request by
Dermata Therapeutics, Inc. that
the effective date of the above-referenced registration statement
be accelerated to 3:00 p.m. (Eastern Time), or as soon as
practicable thereafter, on March 16, 2023, pursuant to Rule 461
under the Securities Act. Wainwright affirms that it is aware of
its obligations under the Securities Act as they pertain to the
best efforts offering pursuant to the Registration
Statement.
Very
truly
yours,
H.C.
WAINWRIGHT & CO., LLC
|
|
H.C.
WAINWRIGHT & CO., LLC
|
|
|
|
|
|
|
|
|
By:
|
/s/
Edward
D. Silvera
|
|
|
|
|
Edward D.
Silvera
|
|
|
|
|
Chief Operating
Officer
|
|
430
Park Avenue | New York, NY 10022 | 212.356.0500 |
www.hcwco.com
Member:
FINRA/SIPC
